Ipamorelin
Ipamorelin was introduced in Phase II clinical trials for the treatment
of intestinal pseudo-obstruction (POI), sponsored by Helsinn
Therapeutics. However, in patients undergoing intestinal resection,
ipamorelin does not shorten the time for the first meal intake compared
to placebo [30]. The Phase II clinical trial below showed no
significant difference in measurable colonic functions between
ipamorelin and placebo [31]. Due to these disappointing results, its
development was halted.